Risks
4 risks
Risk Intelligence
Chinese overcapacity and pricing pressure
View Risks →Clean Science and Technology Limited — Q3 FY26
Clean Science reported a weak Q3 FY26 with consolidated revenue of ₹216 crore, down 21% YoY, driven by volume decline of 19% and pricing pressure of 2%.
bearish
high
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Clean Science reported a weak Q3 FY26 with consolidated revenue of ₹216 crore, down 21% YoY, driven by volume decline of 19% and pricing pressure of 2%. EBITDA margin contracted to 33% (consolidated) and PAT stood at ₹46 crore. The performance chemicals segment was hit hardest, with MEHQ and BHA volumes declining due to Chinese competition and tariff-related destocking in North America. The FMCG segment lost a key customer in China for 4-MAP. On the positive side, the HALS business grew 55% YoY to 810 tons, and the subsidiary Clean Phenino reached breakeven. The new hydroquinone/catechol plant was commercialized in December, expected to improve margins for downstream products. Management refrained from providing near-term margin guidance, citing continued uncertainty from tariffs and Chinese pricing. Risk: Further pricing erosion from Chinese overcapacity could persist for multiple quarters.
क्लीन साइंस की तीसरी तिमाही कमजोर रही। कंपनी की कुल कमाई ₹216 करोड़ रही, जो पिछले साल से 21% कम है। इसकी वजह बिक्री में 19% और कीमतों में 2% की गिरावट है। मुनाफा 33% घटकर ₹46 करोड़ रह गया। सबसे ज्यादा नुकसान परफॉरमेंस केमिकल्स को हुआ, क्योंकि चीन से सस्ते माल और अमेरिका में टैरिफ के कारण ग्राहकों ने स्टॉक कम किया। एफएमसीजी सेगमेंट ने चीन में एक बड़ा ग्राहक खो दिया। अच्छी बात यह है कि एचएएलएस बिजनेस 55% बढ़ा और नई फैक्ट्री दिसंबर में शुरू हुई, जिससे आगे मुनाफा बढ़ सकता है। कंपनी ने भविष्य के मुनाफे का अनुमान नहीं दिया, क्योंकि चीन की सस्ती कीमतों और टैरिफ से अनिश्चितता है। खतरा: चीन का सस्ता माल आने वाली तिमाहियों में भी दबाव बना सकता है।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
HALS Sales Volume
810 tons
+55% YoY
HALS volume grew 55% YoY to 810 tons in Q3, driven by favorable product mix and higher contribution from 944.
Top 4 Products Contribution
75%
-5pp QoQ
Contribution of top 4 products to standalone revenue declined to 75% from 80% in Q2 due to softer volumes.
HALS Blended Realization
₹425/kg
flat QoQ
Blended realization for HALS portfolio was ₹425/kg in Q3, with 944 contributing 20% of portfolio.
Performance Chemical 1 Revenue at 80% Utilization
₹260 crore
-19% vs earlier estimate
Expected revenue from PC1 at 80% utilization revised down to ₹260 crore from ₹320 crore due to price declines.
Fast read
Guidance and risk preview
The PC2 plant is expected to start production by May-June 2026, with revenues beginning in Q4 FY27 after teething issues and customer approvals.
Chinese competitors have increased capacity in hydroquinone and MEHQ, driving prices to all-time lows and pressuring Clean Science's margins.
View Risks →